On Monday, Jefferies analyst Matthew Taylor revised the stock rating for Nevro Corp (NYSE:NVRO), elevating it from Underperform to Hold. Accompanying this upgrade, the price target also saw an ...
Nevro Corp. NVRO is well-poised for growth in the coming quarters, courtesy of its research and development (R&D) edge. The optimism, led by a solid first-quarter 2024 performance and continued ...
The medical device maker's fourth-quarter results thrashed analysts' estimates. Investors were likely more concerned with the apparently growing influence of an activist investor. Despite convincing ...
Globus Medical (NYSE:GMED) said it has agreed to buy Nevro (NVRO) through an all-cash deal with an equity value of around ...
Dublin, March 04, 2020 (GLOBE NEWSWIRE) -- The "Neurostimulation Devices Global Market Report 2020" report has been added to ResearchAndMarkets.com's offering. The global neurostimulation devices ...
Boston Scientific won $20 million in patent case against Nevro last year Two related trials were scheduled for next year (Reuters) - Medical-device maker Boston Scientific Corp has agreed to pay Nevro ...
REDWOOD CITY, Calif., Sept. 19, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic ...
For the fourth quarter, Nevro's revenue inched up by 2% year over year to just over $116 million. On the bottom line, it narrowed its GAAP net loss considerably to slightly over $7 million ($0.25 per ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback